Dr Andrejs Braun

Dr Andrejs Braun

PhD, FHEA
Centre: Haemato-Oncology
Lecturer in Haemato-Oncology
This email address is being protected from spambots. You need JavaScript enabled to view it.

QMUL Directory


I work on antibody therapies for lymphoma and the epigenetics of somatic hypermutation in normal and malignant B cells

Research Details

Our group is interested in the mechanisms of tumour clearance in response to targeted therapy with monoclonal antibodies. In particular, we aim to increase our understanding of the molecular pathways leading to non-apoptotic forms of cell death after ligation of surface antigens in lymphoma and leukaemia cells.

At the systemic level, we are interested in how targeted therapy modulates the tumour niche via secretory and metabolic changes and what impact modulation of the stroma has on tumour growth and clearance.

From an applied cancer therapy perspective, we are interested in establishing the biological basis of synergy between various forms of targeted therapy and conventional radio- and chemotherapy.

Profile

Sept 2013 – present Lecturer, Centre for Haemato-Oncology. Barts Cancer Institute. Queen Mary, University of London.

Apr 2009 – Sept 2013. Postdoctoral Research Associate. Beatson Institute for Cancer Research. University of Glasgow, Glasgow. UK.

Jun 2004 – Sept 2008. Cancer Research UK PhD studentship. Paterson Institute for Cancer Research. University of Manchester.

Nov 2002 – Jun 2004. Visiting Research Fellow. Cancer Sciences Division, University of Southampton, Southampton. UK

Funding

  • Higher Education Funding Council for England (HEFCE)
  • 2017 – 2019 Kay Kendall Leukaemia Fund – project grant £155,671
  • 2014 – 2017 Barry Reed Cancer Trust – PhD studentship £76,000
  • 2016 – 2020 “Bolashak” fellowship programme, Republic of Kazakhstan – PhD studentship £130,000

Key Publications

Dou Z, Xu C, Donahue G, Shimi T, Pan JA, Zhu J, Ivanov A, Capell BC, Drake AM, Shah PP, Catanzaro JM, Daniel Ricketts M, Lamark T, Adam SA, Marmorstein R, Zong WX, Johansen T, Goldman RD, Adams PD, Berger SL. Autophagy mediates degradation of nuclear lamina. Nature. 2015 2015 Nov 5;527(7576):105-9 PMID: 26524528 

Ivanov A, Pawlikowski J, Manoharan I, van Tuyn J, Nelson DM, Rai TS, Shah PP, Hewitt G, Korolchuk VI, Passos JF, Wu H, Berger SL, Adams PD. Lysosome-mediated processing of chromatin in senescence. J Cell Biol. 2013 Jul 8;202(1):129-43. PMID: 23816621

  • Rockefeller University Press “Biobytes” podcast for this article.

Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan CH, Tutt A, Beers SA, Glennie MJ, Cragg MS, Illidge TM. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood. 2011 Apr 28;117(17):4519-29. PMID: 21378274

Ivanov A, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL, Potter KN, Murray S, Chan CH, Klymenko T, Erenpreisa J, Glennie MJ, Illidge TM, Cragg MS. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest. 2009 Aug;119(8):2143-59. PMID: 19620786

  • This article was featured on the BBC.

ORCID ID: 0000-0003-0925-5598


Further Publications

For additional publications, please click here.


I work on antibody therapies for lymphoma and the epigenetics of somatic hypermutation in normal and malignant B cells

External Activities

  • Member of Queen Mary University of London Senate, 2015 – 2019
  • Medical Education Committee. Barts and the London School of Medicine and Dentistry.
  • Departmental teaching lead – Centre for Haemato-Oncology. Barts Cancer Institute.
  • Module lead – Cancer. MBBS (Medicine) Year 2 and Graduate Entry Programme.
  • Module lead – Introduction to Cancer Therapies. MBBS (Medicine) SSC2. Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK.
  • Module lead – Targeted Therapies and Immunotherapy of Haematological Malignancies. MSc Molecular Pathology and Genomics. Queen Mary University of London, UK.
  • Module co-lead – Cancer Biology. MSc Cancer Therapeutics. Queen Mary University of London, UK.
  • OSCE2, OSCE 3, OSCE4 and OSCE5 (finals) examiner – Barts and the London School of Medicine and Dentistry.
  • A100 MBBS entry interviewer. Barts and the London School of Medicine and Dentistry.
  • Undergraduate Mentor: MBBS Years 1 and 2. Barts and the London School of Medicine and Dentistry.
  • Exam board: MSc Cancer Therapeutics and MSc Molecular Pathology and Genomics.
  • MBBS Phase 1 committee: Barts and the London School of Medicine and Dentistry.

News

  • November 2015: Collaborative work on autophagy and anti-tumour effects published in Nature

See other researchers working on:

Blood cancers Cell Signalling Immunology Leukaemia Lymphoma
This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.